(Q51565210)

7 April 2018

title

Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance-related polycystic ovary syndrome. (English)

1 reference

7 April 2018

polycystic ovary syndrome

main subject

1 reference

1 reference

1 reference

1 reference

Hasegawa I

1

1 reference

7 April 2018

Murakawa H

2

1 reference

7 April 2018

Suzuki M

3

1 reference

7 April 2018

Yamamoto Y

4

1 reference

7 April 2018

Kurabayashi T

5

1 reference

7 April 2018

Tanaka K

6

1 reference

7 April 2018

language of work or name

English

0 references

publication date

1 February 1999

1 reference

7 April 2018

published in

Fertility and Sterility

1 reference

7 April 2018

volume

71

1 reference

7 April 2018

issue

2

1 reference

7 April 2018

page(s)

323-327

1 reference

7 April 2018

Polycystic ovary syndrome

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2898%2900454-3

Insulin resistant and non-resistant polycystic ovary syndrome represent two clinical and endocrinological subgroups.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2898%2900454-3

A decade's experience with an individualized clomiphene treatment regimen including its effect on the postcoital test

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2898%2900454-3

Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2898%2900454-3

Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2898%2900454-3

The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2898%2900454-3

Insulin receptors in the central nervous system: localization, signalling mechanisms and functional aspects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2898%2900454-3

Insulin enhancement of luteinizing hormone and follicle-stimulating hormone release by cultured pituitary cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2898%2900454-3

Insulin-like growth factor I and insulin potentiate luteinizing hormone-induced androgen synthesis by rat ovarian thecal-interstitial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2898%2900454-3

Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2898%2900454-3

Dyslipidaemia is associated with insulin resistance in women with polycystic ovaries.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2898%2900454-3

Dyslipidaemia in polycystic ovarian syndrome: different groups, different aetiologies?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2898%2900454-3

Hyperandrogenic anovulation (PCOS): a unique disorder of insulin action associated with an increased risk of non-insulin-dependent diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2898%2900454-3

10.1016/S0015-0282(98)00454-3

7 January 2021

Identifiers

DOI

1 reference

7 April 2018

PubMed ID

9988406

1 reference

7 April 2018